当前位置：
X-MOL 学术
›
JAMA Neurol.
›
论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Downstream Biomarker Effects of Gantenerumab or Solanezumab in Dominantly Inherited Alzheimer Disease: The DIAN-TU-001 Randomized Clinical Trial.
JAMA Neurology ( IF 29.0 ) Pub Date : 2024-04-29 , DOI: 10.1001/jamaneurol.2024.0991 Olivia Wagemann 1, 2 , Haiyan Liu 1 , Guoqiao Wang 3 , Xinyu Shi 3 , Tobias Bittner 4 , Marzia A. Scelsi 5 , Martin R. Farlow 6 , David B. Clifford 1 , Charlene Supnet-Bell 1 , Anna M. Santacruz 1 , Andrew J. Aschenbrenner 1 , Jason J. Hassenstab 1 , Tammie L. S. Benzinger 7 , Brian A. Gordon 7 , Kelley A. Coalier 8 , Carlos Cruchaga 9 , Laura Ibanez 1, 9 , Richard J. Perrin 1, 10 , Chengjie Xiong 3 , Yan Li 1 , John C. Morris 1 , James J. Lah 11 , Sarah B. Berman 12 , Erik D. Roberson 13 , Christopher H. van Dyck 14 , Douglas Galasko 15 , Serge Gauthier 16 , Ging-Yuek R. Hsiung 17 , William S. Brooks 18, 19 , Jérémie Pariente 20 , Catherine J. Mummery 21 , Gregory S. Day 22 , John M. Ringman 23 , Patricio Chrem Mendez 24 , Peter St. George-Hyslop 25 , Nick C. Fox 21 , Kazushi Suzuki 26 , Hamid R. Okhravi 27 , Jasmeer Chhatwal 28 , Johannes Levin 2, 29, 30 , Mathias Jucker 31, 32 , John R. Sims 33 , Karen C. Holdridge 33 , Nicholas K. Proctor 33 , Roy Yaari 33 , Scott W. Andersen 33 , Michele Mancini 33 , Jorge Llibre-Guerra 1 , Randall J. Bateman 1 , Eric McDade 1 , Alisha J. Daniels 34 , Laura Courtney 34 , Xiong Xu 34 , Ruijin Lu 34 , Emily Gremminger 34 , Erin Franklin 34 , Laura Ibanez 34 , Gina Jerome 34 , Elizabeth Herries 34 , Jennifer Stauber 34 , Bryce Baker 34 , Matthew Minton 34 , Alison M. Goate 34 , Alan E. Renton 34 , Danielle M. Picarello 34 , Russ Hornbeck 34 , Allison Chen 34 , Charles Chen 34 , Shaney Flores 34 , Nelly Joseph-Mathurin 34 , Steve Jarman 34 , Kelley Jackson 34 , Sarah Keefe 34 , Deborah Koudelis 34 , Parinaz Massoumzadeh 34 , Austin McCullough 34 , Nicole McKay 34 , Joyce Nicklaus 34 , Christine Pulizos 34 , Qing Wang 34 , Edita Sabaredzovic 34 , Hunter Smith 34 , Jalen Scott 34 , Ashlee Simmons 34 , Jacqueline Rizzo 34 , Jennifer Smith 34 , Sarah Stout 34 , Celeste M. Karch 34 , Jacob Marsh 34 , David M. Holtzman 34 , Nicolas Barthelemy 34 , Jinbin Xu 34 , James M. Noble 34 , Snezana Ikonomovic 34 , Neelesh K. Nadkarni 34 , Neill R. Graff-Radford 34 , Takeshi Ikeuchi 34 , Kensaku Kasuga 34 , Yoshiki Niimi 34 , Edward D. Huey 34 , Stephen Salloway 34 , Peter R. Schofield 34 , Jacob A. Bechara 34 , Ralph Martins 34 , David M. Cash 34 , Natalie S. Ryan 34 , Christoph Laske 34 , Anna Hofmann 34 , Elke Kuder-Buletta 34 , Susanne Graber-Sultan 34 , Ulrike Obermueller 34 , Yvonne Roedenbeck 34 , Jonathan Vӧglein 34 , Jae-Hong Lee 34 , Jee Hoon Roh 34 , Raquel Sanchez-Valle 34 , Pedro Rosa-Neto 34 , Ricardo F. Allegri 34 , Ezequiel Surace 34 , Silvia Vazquez 34 , Francisco Lopera 34 , Yudy Milena Leon 34 , Laura Ramirez 34 , David Aguillon 34 , Allan I. Levey 34 , Erik C.B Johnson 34 , Nicholas T. Seyfried 34 , Anne M. Fagan 34 , Hiroshi Mori 34 , Colin Masters 34 ,
JAMA Neurology ( IF 29.0 ) Pub Date : 2024-04-29 , DOI: 10.1001/jamaneurol.2024.0991 Olivia Wagemann 1, 2 , Haiyan Liu 1 , Guoqiao Wang 3 , Xinyu Shi 3 , Tobias Bittner 4 , Marzia A. Scelsi 5 , Martin R. Farlow 6 , David B. Clifford 1 , Charlene Supnet-Bell 1 , Anna M. Santacruz 1 , Andrew J. Aschenbrenner 1 , Jason J. Hassenstab 1 , Tammie L. S. Benzinger 7 , Brian A. Gordon 7 , Kelley A. Coalier 8 , Carlos Cruchaga 9 , Laura Ibanez 1, 9 , Richard J. Perrin 1, 10 , Chengjie Xiong 3 , Yan Li 1 , John C. Morris 1 , James J. Lah 11 , Sarah B. Berman 12 , Erik D. Roberson 13 , Christopher H. van Dyck 14 , Douglas Galasko 15 , Serge Gauthier 16 , Ging-Yuek R. Hsiung 17 , William S. Brooks 18, 19 , Jérémie Pariente 20 , Catherine J. Mummery 21 , Gregory S. Day 22 , John M. Ringman 23 , Patricio Chrem Mendez 24 , Peter St. George-Hyslop 25 , Nick C. Fox 21 , Kazushi Suzuki 26 , Hamid R. Okhravi 27 , Jasmeer Chhatwal 28 , Johannes Levin 2, 29, 30 , Mathias Jucker 31, 32 , John R. Sims 33 , Karen C. Holdridge 33 , Nicholas K. Proctor 33 , Roy Yaari 33 , Scott W. Andersen 33 , Michele Mancini 33 , Jorge Llibre-Guerra 1 , Randall J. Bateman 1 , Eric McDade 1 , Alisha J. Daniels 34 , Laura Courtney 34 , Xiong Xu 34 , Ruijin Lu 34 , Emily Gremminger 34 , Erin Franklin 34 , Laura Ibanez 34 , Gina Jerome 34 , Elizabeth Herries 34 , Jennifer Stauber 34 , Bryce Baker 34 , Matthew Minton 34 , Alison M. Goate 34 , Alan E. Renton 34 , Danielle M. Picarello 34 , Russ Hornbeck 34 , Allison Chen 34 , Charles Chen 34 , Shaney Flores 34 , Nelly Joseph-Mathurin 34 , Steve Jarman 34 , Kelley Jackson 34 , Sarah Keefe 34 , Deborah Koudelis 34 , Parinaz Massoumzadeh 34 , Austin McCullough 34 , Nicole McKay 34 , Joyce Nicklaus 34 , Christine Pulizos 34 , Qing Wang 34 , Edita Sabaredzovic 34 , Hunter Smith 34 , Jalen Scott 34 , Ashlee Simmons 34 , Jacqueline Rizzo 34 , Jennifer Smith 34 , Sarah Stout 34 , Celeste M. Karch 34 , Jacob Marsh 34 , David M. Holtzman 34 , Nicolas Barthelemy 34 , Jinbin Xu 34 , James M. Noble 34 , Snezana Ikonomovic 34 , Neelesh K. Nadkarni 34 , Neill R. Graff-Radford 34 , Takeshi Ikeuchi 34 , Kensaku Kasuga 34 , Yoshiki Niimi 34 , Edward D. Huey 34 , Stephen Salloway 34 , Peter R. Schofield 34 , Jacob A. Bechara 34 , Ralph Martins 34 , David M. Cash 34 , Natalie S. Ryan 34 , Christoph Laske 34 , Anna Hofmann 34 , Elke Kuder-Buletta 34 , Susanne Graber-Sultan 34 , Ulrike Obermueller 34 , Yvonne Roedenbeck 34 , Jonathan Vӧglein 34 , Jae-Hong Lee 34 , Jee Hoon Roh 34 , Raquel Sanchez-Valle 34 , Pedro Rosa-Neto 34 , Ricardo F. Allegri 34 , Ezequiel Surace 34 , Silvia Vazquez 34 , Francisco Lopera 34 , Yudy Milena Leon 34 , Laura Ramirez 34 , David Aguillon 34 , Allan I. Levey 34 , Erik C.B Johnson 34 , Nicholas T. Seyfried 34 , Anne M. Fagan 34 , Hiroshi Mori 34 , Colin Masters 34 ,
Affiliation
Effects of antiamyloid agents, targeting either fibrillar or soluble monomeric amyloid peptides, on downstream biomarkers in cerebrospinal fluid (CSF) and plasma are largely unknown in dominantly inherited Alzheimer disease (DIAD).
中文翻译：
Gantenerumab 或 Solanezumab 对显性遗传性阿尔茨海默病的下游生物标志物影响：DIAN-TU-001 随机临床试验。
在显性遗传性阿尔茨海默病 (DIAD) 中，针对纤维状或可溶性单体淀粉样肽的抗淀粉样蛋白药物对脑脊液 (CSF) 和血浆中下游生物标志物的影响在很大程度上尚不清楚。
更新日期：2024-04-29
中文翻译：
Gantenerumab 或 Solanezumab 对显性遗传性阿尔茨海默病的下游生物标志物影响：DIAN-TU-001 随机临床试验。
在显性遗传性阿尔茨海默病 (DIAD) 中，针对纤维状或可溶性单体淀粉样肽的抗淀粉样蛋白药物对脑脊液 (CSF) 和血浆中下游生物标志物的影响在很大程度上尚不清楚。
京公网安备 11010802027423号